

## Special Issue

# Advances in High-Grade Serous Ovarian Cancer: New Perspectives Promising Hope for Eradicating a Devastating Disease

### Message from the Guest Editor

Within the histotypes of ovarian cancer, high-grade serous is the most common and aggressive form, accounting for approximately 70–75% of all ovarian cancer cases, often originating in the fallopian tubes and characterized by rapid progression and poor prognosis. This disease is habitually diagnosed at an advanced stage due to vague symptoms. Treatment usually involves a combination of surgery and chemotherapy with platinum derivatives. This therapy is initially often efficient. However, the disease almost always relapses with a platinum-resistant phenotype (also known as platinum-resistant ovarian cancer or PROC). Once they develop PROC, patients receive therapies that are poorly effective, leading to a median overall survival of only 12 months. This Special Issue intends to bring to the readers novel information related to risk factors, prevention, symptoms, screening, early diagnosis and management, epidemiology, optimization of standard of care, recurrent platinum-resistant disease management, novel therapeutic approaches including repurposed drugs and vaccines, use of artificial intelligence for diagnosis and treatment, life expectancy, quality of life, and prognosis.

---

### Guest Editor

Prof. Dr. Carlos M. Telleria  
Experimental Pathology Unit, Department of Pathology, McGill University, Montreal, QC H3A 2B4, Canada

---

### Deadline for manuscript submissions

30 November 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/243676](https://mdpi.com/si/243676)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)